{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T17:45:06Z","timestamp":1759340706552},"reference-count":38,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,10,9]],"date-time":"2008-10-09T00:00:00Z","timestamp":1223510400000},"content-version":"vor","delay-in-days":3844,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Pharmacy Therapeu"],"published-print":{"date-parts":[[1998,4]]},"abstract":"<jats:p> <jats:italic>\n            Background:\n          <\/jats:italic> The important prophylactic role of antithrombotic therapy against stroke in nonrheumatic atrial fibrillation (AF) has been clearly established in recent clinical trials. There have been suggestions, however, that practice has been slow to change in light of the findings of these trials<\/jats:p><jats:p> <jats:italic>\n            Aim: \n          <\/jats:italic>To review cases of AF at the major teaching hospital in Tasmania, Australia, to determine whether the recommendations from the results of the trials had been translated into local clinical practice<\/jats:p><jats:p> <jats:italic>\n            Methods: \n          <\/jats:italic>A retrospective review of the medical records for consecutive patients who had AF documented on ECG between 1 January and 30 June 1997 was performed. An extensive range of demographic and clinical variables were recorded for patients with chronic or paroxysmal nonrheumatic AF. These included antithrombotic and other drug therapy at admission and discharge from hospital care, risk factors for stroke, contraindications to antithrombotic use, and incidents of ischaemic stroke and bleeding complications that occurred during the period from January 1996 up to 3 months after the hospital admission that was studied<\/jats:p><jats:p> <jats:italic>\n            Results: The 228 patients included in the study had a mean (\u00b1SD) age of 75\u00b73\u00b110\u00b79 years. Sixty\u2010eight per cent had chronic AF and 32% had paroxysmal AF. According to two risk stratification criteria, 91% and 86% of the patients with previously diagnosed chronic or paroxysmal nonrheumatic AF (\n\t\t\t\t\t\tn<\/jats:italic>=186) had a high risk of developing stroke at the time of admission to hospital care. However, less than one\u2010third of these patients were receiving warfarin (or warfarin plus aspirin), with almost another one\u2010third receiving no antithrombotic agent. Of those who were not taking warfarin, about 60% had no apparent contraindication to warfarin. For those high risk patients who had a possible contraindication to warfarin, only approximately one\u2010third had been prescribed aspirin. Only a slight increase in the use of antithrombotic agents had occurred by the time of discharge from hospital care. The majority of international normalized ratio (INR) values on admission for patients who had been taking warfarin were subtherapeutic. The estimated annual incidence of bleeding complications in patients taking warfarin was 15\u00b70% overall, 5\u00b70% for major bleeds and 3\u00b78% for intracranial haemorrhages<\/jats:p><jats:p> <jats:italic>\n            Conclusions: \n          <\/jats:italic>While a number of published trials have demonstrated that antithrombotic agents confer substantial protection against stroke in patients with nonrheumatic AF, the drugs were underused in our setting. There is a need to improve antithrombotic use and to develop a better monitoring system for the provision of safer and more effective antithrombotic therapy.<\/jats:p>","DOI":"10.1046\/j.1365-2710.1998.00148.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T04:31:19Z","timestamp":1047443479000},"page":"97-106","source":"Crossref","is-referenced-by-count":12,"title":["Review of antithrombotic drug usage in atrial fibrillation"],"prefix":"10.1155","volume":"23","author":[{"family":"Ang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Friesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Vial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,10,9]]},"reference":[{"key":"e_1_2_3_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1996.03384.x"},{"key":"e_1_2_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)80348-9"},{"key":"e_1_2_3_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.28.10.973"},{"key":"e_1_2_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)89116-3"},{"key":"e_1_2_3_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7022.45"},{"key":"e_1_2_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)91200-2"},{"key":"e_1_2_3_8_2","first-page":"527","article-title":"Stroke Prevention in Atrial Fibrillation Investigators","volume":"84","year":"1991","journal-title":"Stroke prevention in atrial fibrillation study. Final resultsCirculation"},{"key":"e_1_2_3_9_2","first-page":"1505","article-title":"The Boston Area Anticoagulation Trial for Atrial Fibrillation investigators","volume":"323","year":"1990","journal-title":"The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillationNew England Journal of Medicine"},{"key":"e_1_2_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(91)90585-W"},{"key":"e_1_2_3_11_2","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation","volume":"327","author":"Ezekowitz MD","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_3_12_2","first-page":"687","article-title":"WStroke Prevention in Atrial Fibrillation Investigators","volume":"343","year":"1994","journal-title":"Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II StudyLancet"},{"key":"e_1_2_3_13_2","first-page":"1449","article-title":"Atrial Fibrillation Investigators","volume":"154","year":"1994","journal-title":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trialsArchives of Internal Medicine"},{"key":"e_1_2_3_14_2","first-page":"1255","article-title":"EAFT (European Atrial Fibrillation Trial) study group","volume":"342","year":"1993","journal-title":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor strokeLancet"},{"key":"e_1_2_3_15_2","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1136\/bmj.305.6867.1457","article-title":"Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective","volume":"305","author":"Gustaffson C","year":"1992","journal-title":"British Medical Journal"},{"key":"e_1_2_3_16_2","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1001\/jama.1995.03530230025025","article-title":"Cost\u2010effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation","volume":"274","author":"Gage BF","year":"1995","journal-title":"Journal of the American Medical Association"},{"key":"e_1_2_3_17_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/bmj.312.7024.175","article-title":"ABC of atrial fibrillation. Atrial fibrillation in hospital and general practice","volume":"312","author":"Lip GYH","year":"1996","journal-title":"British Medical Journal"},{"key":"e_1_2_3_18_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1996.tb122211.x"},{"key":"e_1_2_3_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.71.1.92"},{"key":"e_1_2_3_20_2","first-page":"1313","article-title":"Survey of use of anticoagulation in atrial fibrillation","volume":"307","author":"Bath PMW","year":"1993","journal-title":"British Medical Journal"},{"key":"e_1_2_3_21_2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archinte.1997.00440250097011","article-title":"Is warfarin underused in the treatment of elderly persons with atrial fibrillation?","volume":"157","author":"Whittle J","year":"1997","journal-title":"Archives of Internal Medicine"},{"key":"e_1_2_3_22_2","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1001\/archinte.1996.00440190053006","article-title":"Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals","volume":"156","author":"Albers GW","year":"1996","journal-title":"Archives of Internal Medicine"},{"key":"e_1_2_3_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.28.1.72"},{"key":"e_1_2_3_24_2","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1001\/archinte.1996.00440210043004","article-title":"National patterns of warfarin use in atrial fibrillation","volume":"156","author":"Stafford RS","year":"1996","journal-title":"Archives of Internal Medicine"},{"key":"e_1_2_3_25_2","first-page":"285","article-title":"A survey of atrial fibrillation in general practice. The West Birmingham atrial fibrillation project","volume":"47","author":"Lip GYH","year":"1997","journal-title":"British Journal of General Practice"},{"key":"e_1_2_3_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.314.7093.1529"},{"key":"e_1_2_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/25.4.307"},{"key":"e_1_2_3_28_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.6.1598"},{"key":"e_1_2_3_29_2","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/archinte.1997.00440300080006","article-title":"Atrial fibrillation and stroke prevention with warfarin in the long\u2010term care setting","volume":"157","author":"Gurwitz JH","year":"1997","journal-title":"Archives of Internal Medicine"},{"key":"e_1_2_3_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050328"},{"key":"e_1_2_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0967-5868(97)90099-0"},{"key":"e_1_2_3_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199211123272009"},{"key":"e_1_2_3_33_2","unstructured":"ThomasJ1996Australian Prescription Products Guide 25th edn pp. 724\u2013726. Melbourne Victoria: Australian Pharmaceutical Publishing Company Limited."},{"key":"e_1_2_3_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430030071008"},{"key":"e_1_2_3_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809703101012"},{"key":"e_1_2_3_36_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-11-199606010-00004"},{"key":"e_1_2_3_37_2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/jppr1997274328","article-title":"Anticoagulation in older people","volume":"27","author":"Thurlow PJ","year":"1997","journal-title":"Australian Journal of Hospital Pharmacy"},{"key":"e_1_2_3_38_2","doi-asserted-by":"publisher","DOI":"10.4065\/70.8.725"},{"key":"e_1_2_3_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608223350802"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2710.1998.00148.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2710.1998.00148.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T14:14:34Z","timestamp":1726150474000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2710.1998.00148.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1998,4]]}},"alternative-id":["10.1046\/j.1365-2710.1998.00148.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2710.1998.00148.x","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"type":"print","value":"0269-4727"}],"subject":[],"published":{"date-parts":[[1998,4]]}}}